About this trial
As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to be elucidated. The collection of standardized data within a patientheque as part of a multi-year follow-up will facilitate the study of the characteristics of these diseases. This may, in particular, address the main objective of identifying predictors of relapse, as well as secondary objectives for predictive factors of mortality, infectious, cardiovascular or neoplastic complications that affect the prognosis of vasculitis in order to establish a more appropriate management of the patients concerned.
Eligibility criteria
Qualifiers
Major patients with no upper age limit.
Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest.
Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference.
Patient affiliated with Social Security
Disqualifiers
Minor
Patients unable to consent.
Patients refusing to participate in research
Patient under legal protection (tutelage, curatorship)
Trial design
Treatments tested in this trial
- Blood samples (80 mL)
- Fecal samples
- Urinary sample (20-40 mL)
- Questionnaires